Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 2/2008

01.12.2008 | Short Report

Molecular diagnosis of German patients with late-onset glycogen storage disease type II

verfasst von: P. R. Joshi, D. Gläser, S. Schmidt, M. Vorgerd, M. Winterholler, K. Eger, S. Zierz, M. Deschauer

Erschienen in: Journal of Inherited Metabolic Disease | Sonderheft 2/2008

Einloggen, um Zugang zu erhalten

Summary

In patients with late-onset glycogen storage disease type II, one mutation, c.−32−13T>G, in the α-glucosidase (GAA) gene is identified frequently in European populations from different regions along with many rarer mutations. We have performed molecular genetic investigations in 18 German index patients with late-onset disease. The c.−32−13T>G, c.525delT (p.Glu176fsX45), and c.2481+102_2646+31del mutations were detected by PCR/restriction enzyme digest. Other mutations were detected by sequencing. All patients were compound heterozygous and 17 patients harboured the c.−32−13T>G mutation. Seven other previously described mutations (including the c.−32−13T>G) were identified, of which the p.C103G (c.307T>G) and the c.2481+102_2646+31del mutations were present each in three unrelated patients. Sequencing revealed five novel mutations. Conclusions: Genetic testing was able to identify the genetic defects in all patients and screening of the c.−32−13T>G mutation identified 94% of the cases. This is important for quick and reliable diagnosis, especially in view of enzyme replacement. Among the rarer mutations, c.2481+102_2646+31del and p.C103G are rather frequent in Germany.
Literatur
Zurück zum Zitat Bodamer OA, Haas D, Hermans MM, Reuser AJ, Hoffmann GF (2002) l-Alanine supplementation in late infantile glycogen storage disease type II. Pediatr Neurol 27: 145–146.PubMedCrossRef Bodamer OA, Haas D, Hermans MM, Reuser AJ, Hoffmann GF (2002) l-Alanine supplementation in late infantile glycogen storage disease type II. Pediatr Neurol 27: 145–146.PubMedCrossRef
Zurück zum Zitat Boerkoel CF, Exelbert R, Nicastri C, et al (1995) Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet 56: 887–897.PubMed Boerkoel CF, Exelbert R, Nicastri C, et al (1995) Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet 56: 887–897.PubMed
Zurück zum Zitat Hermans MM, Kroos MA, de Graaff E, Oostra BA, Reuser AJ (1993) Two mutations affecting the transport and maturation of lysosomal alpha-glucosidase in an adult case of glycogen storage disease type II. Hum Mutat 12: 268–273.CrossRef Hermans MM, Kroos MA, de Graaff E, Oostra BA, Reuser AJ (1993) Two mutations affecting the transport and maturation of lysosomal alpha-glucosidase in an adult case of glycogen storage disease type II. Hum Mutat 12: 268–273.CrossRef
Zurück zum Zitat Hermans MM, De Graaff E, Kroos MA, et al (1994) The effect of a single base pair deletion (T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet 3: 2213–2218.PubMedCrossRef Hermans MM, De Graaff E, Kroos MA, et al (1994) The effect of a single base pair deletion (T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet 3: 2213–2218.PubMedCrossRef
Zurück zum Zitat Hermans MPP, van Leenen D, Kroos MA, et al (2004) Twenty-two novel mutations in the lysosomal α-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23: 47–56.PubMedCrossRef Hermans MPP, van Leenen D, Kroos MA, et al (2004) Twenty-two novel mutations in the lysosomal α-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23: 47–56.PubMedCrossRef
Zurück zum Zitat Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R (1994a) A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSD II). Hum Mol Genet 3: 1081–1087.PubMedCrossRef Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R (1994a) A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSD II). Hum Mol Genet 3: 1081–1087.PubMedCrossRef
Zurück zum Zitat Huie ML, Chen AS, Tsujino S, et al (1994b) Aberrant splicing in adult onset glycogen storage disease type II (GSD II): molecular identification of an IVS1 (−13T>G) mutation in a majority of patients and a novel IVS10 (+1GT>CT) mutation. Hum Mol Genet 3: 2231–2236.PubMedCrossRef Huie ML, Chen AS, Tsujino S, et al (1994b) Aberrant splicing in adult onset glycogen storage disease type II (GSD II): molecular identification of an IVS1 (−13T>G) mutation in a majority of patients and a novel IVS10 (+1GT>CT) mutation. Hum Mol Genet 3: 2231–2236.PubMedCrossRef
Zurück zum Zitat Ko TM, Hwu WL, Lin YW, et al (1999) Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat 13: 380–384.PubMedCrossRef Ko TM, Hwu WL, Lin YW, et al (1999) Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat 13: 380–384.PubMedCrossRef
Zurück zum Zitat Kroos MA, van der Kraan M, van Diggelen OP, et al (1995) Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 32: 836–840.PubMedCrossRef Kroos MA, van der Kraan M, van Diggelen OP, et al (1995) Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 32: 836–840.PubMedCrossRef
Zurück zum Zitat Kroos MA, Pomponio RJ, Hagemans ML, et al (2007) Broad spectrum of Pompe disease in patients with the same c.−32−13T>G haplotype. Neurology 68: 110–115.PubMedCrossRef Kroos MA, Pomponio RJ, Hagemans ML, et al (2007) Broad spectrum of Pompe disease in patients with the same c.−32−13T>G haplotype. Neurology 68: 110–115.PubMedCrossRef
Zurück zum Zitat Laforêt P, Nicolino M, Eymard PB, et al (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype–phenotype correlation. Neurology 55: 1122–1128.PubMed Laforêt P, Nicolino M, Eymard PB, et al (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype–phenotype correlation. Neurology 55: 1122–1128.PubMed
Zurück zum Zitat McCready ME, Carson NL, Chakraborty P, et al (2007) Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II. Mol Genet Metab 92: 325–335.PubMedCrossRef McCready ME, Carson NL, Chakraborty P, et al (2007) Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II. Mol Genet Metab 92: 325–335.PubMedCrossRef
Zurück zum Zitat Montalvo AL, Bembi B, Donnarumma M, et al (2006) Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 27: 999–1006.PubMedCrossRef Montalvo AL, Bembi B, Donnarumma M, et al (2006) Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 27: 999–1006.PubMedCrossRef
Zurück zum Zitat Müller-Felber W, Horvath R, Gempel K, et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17: 698–706.PubMedCrossRef Müller-Felber W, Horvath R, Gempel K, et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17: 698–706.PubMedCrossRef
Zurück zum Zitat Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoles NA (2007) Pompe disease (glycogen storage disease type II) in Argentineans: Clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord 17: 16–22.PubMedCrossRef Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoles NA (2007) Pompe disease (glycogen storage disease type II) in Argentineans: Clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord 17: 16–22.PubMedCrossRef
Zurück zum Zitat Sharma MC, Schultze C, von Moers A, et al (2005) Delayed or late-onset type II glycogenosis with globular inclusions. Acta Neuropathol (Berl) 110: 151–157.CrossRef Sharma MC, Schultze C, von Moers A, et al (2005) Delayed or late-onset type II glycogenosis with globular inclusions. Acta Neuropathol (Berl) 110: 151–157.CrossRef
Zurück zum Zitat Van den Hout JMP, Kamphoven JHJ, Winkel LPF, et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113: 448–457.CrossRef Van den Hout JMP, Kamphoven JHJ, Winkel LPF, et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113: 448–457.CrossRef
Zurück zum Zitat van der Kraan M, Kroos MA, Joosse M, et al (1994) Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun 203: 1535–1541.PubMedCrossRef van der Kraan M, Kroos MA, Joosse M, et al (1994) Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun 203: 1535–1541.PubMedCrossRef
Zurück zum Zitat Vorgerd M, Burwinkel B, Reichmann H, Malin J-P, Kilimann MW (1998) Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients. Neurogenetics 1: 205–211.PubMedCrossRef Vorgerd M, Burwinkel B, Reichmann H, Malin J-P, Kilimann MW (1998) Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients. Neurogenetics 1: 205–211.PubMedCrossRef
Zurück zum Zitat Winchester B, Bali D, Bodamer AO, et al (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93(3): 275–281. Epub 19 Dec. 2007PubMedCrossRef Winchester B, Bali D, Bodamer AO, et al (2008) Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93(3): 275–281. Epub 19 Dec. 2007PubMedCrossRef
Zurück zum Zitat Wokke JHJ, Ausems GEM, van den Boogaard MJH, et al (1995) Genotype–phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 38: 450–454.PubMedCrossRef Wokke JHJ, Ausems GEM, van den Boogaard MJH, et al (1995) Genotype–phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 38: 450–454.PubMedCrossRef
Metadaten
Titel
Molecular diagnosis of German patients with late-onset glycogen storage disease type II
verfasst von
P. R. Joshi
D. Gläser
S. Schmidt
M. Vorgerd
M. Winterholler
K. Eger
S. Zierz
M. Deschauer
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe Sonderheft 2/2008
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-008-0820-2

Weitere Artikel der Sonderheft 2/2008

Journal of Inherited Metabolic Disease 2/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.